3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Mouth Neoplasms
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
1
Sentinel Lymph Node Biopsy (SLNB)
1
Recurrence
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lymphatic Metastasis
1
Endometrial Neoplasms
1
Eccrine Porocarcinoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Carcinoma In Situ
1
Interventions
Magnetic Resonance Spectroscopy
3
aldesleukin
2
Paclitaxel
2
Nivolumab
2
Ifosfamide
2
Cisplatin
2
Adoptive Transfer
2
toripalimab
1
pembrolizumab
1
niraparib
1
lenvatinib
1
fludarabine
1
enfortumab vedotin
1
dostarlimab
1
cabozantinib
1
Ultrasonography
1
Specimen Handling
1
Sentinel Lymph Node Biopsy
1
Magnetic Resonance Imaging
1
Ipilimumab
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Cyclophosphamide
1
CTLA-4 Antigen
1
CP protocol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Penile Neoplasms
×
Sentinel Lymph Node Biopsy
×
Clear all
NCT06666634
2024-10-30
NANOSCAN
The Netherlands Cancer Institute
Phase NA
Recruiting
29 enrolled